Containing “The Great Houdini” of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C
Authors:
- Lars FrelinLFLars Frelin
- Erwin Daniel BrenndörferEBErwin Daniel Brenndörfer
- Anette BrassABAnette Brass
- Ola WeilandOWOla Weiland
- Margaret ChenMCMargaret Chen
- Matti SällbergMSMatti Sällberg
Open Access
- 1 July 2013
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 16 (3-5) , 60-67
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis CMolecular Therapy, 2013
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus InfectionPLOS ONE, 2013
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- Features of responding T cells in cancer and chronic infectionCurrent Opinion in Immunology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis CVaccine, 2009
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3Cell, 2005
- Evasion of intracellular host defence by hepatitis C virusNature, 2005